drugset / Trial / NCT00239655

A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)

NCT00239655 ↗

Phase 2 Terminated 120 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to test MK0812 on disease activity in patients with relapsing-remitting MS. Disease modifying activity will be assessed by measurement of brain lesions via MRI brain scans and an open label extension is offered.

Timeline

Start
2004-08
Primary completion
2005-12
Completion
2006-01

Drugs

EvaluationDrugModalityDoseRoute
Subject MK0812 Small molecule — —